Cipher Pharmaceuticals (TSE:CPH) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cipher Pharmaceuticals announced that their partner, Moberg Pharma, reported disappointing results from a Phase 3 study of MOB-015, a nail fungus treatment, which did not meet its primary endpoint. Despite this setback, Cipher remains focused on its recent acquisition of the Natroba business and sees significant growth potential in the U.S. and international markets.
For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money